<DOC>
	<DOCNO>NCT00673881</DOCNO>
	<brief_summary>The objective study : 1 . To evaluate effect ABT-335 ( choline fenofibrate ) several parameter RCT ( reverse cholesterol transport ) men post-menopausal woman diagnose dyslipidemia ( i.e. , low high-density lipoprotein [ HDL ] cholesterol level elevate triglyceride [ TG ] concentration ) . 2 . To evaluate longitudinal change several parameter RCT subject low HDL . 3 . To obtain pilot data power calculation subsequent comparative study .</brief_summary>
	<brief_title>ABT-335 ( Choline Fenofibrate ) Reverse Cholesterol Transport ( RCT ) Study</brief_title>
	<detailed_description>This trial assess effect ABT-335 RCT measure cholesterol efflux rate appearance cholesterol ( Ra mg/kg/hr ) , cholesterol excretion ( % /day ) , RCT efflux ( mg/kg/day ) de novo cholesterol synthesis ( % ) baseline period ( 7 day ) treatment period ( 94 day ) . The goal use RCT reverse atherosclerosis increase rate cholesterol export `` efflux '' tissue plaque . An increase cholesterol efflux rate shrink arterial plaque decrease static accumulation cholesterol . While currently market drug positive impact RCT increase rate cholesterol excretion body , drug yet approve increase rate cholesterol efflux tissue</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Choline</mesh_term>
	<criteria>1 . Male , nonsmoker , 21 75 year age inclusive . 2 . Female , nonsmoker , 40 75 year age inclusive . 3 . Postmenopausal woman , define lack menses least 2 year age &gt; 55 , OR history document bilateral surgical oophorectomy , confirm elevate folliclestimulating hormone ( FSH ) screening . 4 . HDL concentration ( ≤ 50 mg/dl woman , ≤ 40mg/dl men ) 5 . TG concentration 150500 mg/dl , inclusive 6 . Ability give inform consent 1 . Subject history diabetes mellitus , active hepatitis , gall bladder disease , gastric bypass surgery , clinically significant abnormality screen ( prestudy ) physical examination laboratory test . 2 . Screening laboratory test hematocrit &lt; 30 % , aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &gt; 2X upper limit normal , abnormal thyroidstimulating hormone ( TSH ) , fast glucose ≥126 mg/dl . 3 . Renal impairment creatinine clearance &lt; 80 ml/min . 4 . Treatment within last 6 month drug know alter lipid metabolism include beta blocker , thiazide diuretic , bile acid resin , ezetimibe , fibrates , niacin , fish oil ( see Appendix 1 ) . Washout fibrates permit . 5 . Treatment drug know interact ABT335 , e.g. , warfarin ( see Appendix 1 ) . 6 . Treatment HMG CoA reductase inhibitor ( statin ) within past 4 week ( see Appendix 1 ) . 7 . History allergy egg soy product . 8 . History coronary heart disease ( CHD ) , stroke revascularization procedure six month prior Visit 1 . 9 . Current recent history ( past 12 month ) drug abuse alcohol abuse . Alcohol abuse define &gt; 14 drink per week ( 1 drink = 12 oz beer , 5 oz wine , 1.5 oz hard liquor ) . 10 . Participation another clinical trial exposure investigational agent within 30 day visit 1 . 11 . Individual condition Principal Investigator believe would interfere his/her ability provide inform consent , comply study instruction , might confound interpretation study result put subject undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>